Physician profile
David W Lee
NPI 1528015906
$13,022.25
in general payments reported to CMS, 2019-2025
41 companies · $2,564 in 2025
The $2,564 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2021: $226 · 2022: $687 · 2023: $2,765 · 2024: $5,905 · 2025: $2,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411 · Education: $4,580 · Travel and Lodging: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,410.64 |
| Education | $4,579.94 |
| Travel and Lodging | $1,243.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,870.74 | 2023-2024 | Da Vinci Surgical System |
| Olympus Corporation of The Americas | $1,298.51 | 2023 | Single Use Suction Valve (Sterile), Olympus |
| United Therapeutics Corporation | $1,120.83 | 2019-2024 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $792.95 | 2019-2023 | Breztri, Airsupra |
| Genzyme Corporation | $488.02 | 2024-2025 | |
| Madrigal Pharmaceuticals | $485.26 | 2025 | Rezdiffra |
| Inspire Medical Systems, INC. | $421.17 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $419.46 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $298.16 | 2022-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $293.16 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $289.13 | 2021-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $260.68 | 2024-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $252.60 | 2024-2025 | |
| Abbvie INC. | $210.62 | 2019-2025 | |
| Mml US, INC. | $189.44 | 2023 | Reactiv8 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $147.13 | 2024-2025 | Simponi Aria, Simponi, Stelara |
| Olympus America INC. | $134.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.05 | 2019-2024 | Trulance |
| Abiomed | $110.77 | 2025 | |
| Btg International INC. | $88.13 | 2021 | |
| Vivus LLC | $75.98 | 2025 | Pancreaze, Qsymia |
| Pulmonx Corporation | $72.09 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.80 | 2024 | Ofev |
| Vertex Pharmaceuticals Incorporated | $50.58 | 2019 | |
| Verona Pharma, INC. | $47.26 | 2025 | Ohtuvayre |
| Itamar Medical INC | $43.72 | 2023-2025 | Watchpatone |
| Nevro Corp. | $38.12 | 2019 | |
| Evoke Pharma, INC. | $38.08 | 2025 | |
| Inari Medical, INC. | $36.56 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Baxter Healthcare | $34.71 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $33.70 | 2022 | |
| Lilly USA, LLC | $32.61 | 2024 | Omvoh |
| Pfizer INC. | $28.57 | 2025 | |
| Biosense Webster, INC. | $23.92 | 2025 | Nuvision Ice Catheter |
| Melinta Therapeutics, LLC | $19.38 | 2022 | |
| Pinnacle Biologics, INC | $17.96 | 2025 | Photofrin |
| Insmed, INC. | $17.94 | 2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2023 | Glassia |
| Johnson & Johnson Surgical Vision, INC. | $15.25 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.44 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.